Antibacterial Agents TRIZ Cases

A pharmaceutical solution alters bacterial proteins to restore penicillin sensitivity.

Specific amino acid residues in beta-hairpin peptidomimetics achieve high selectivity against human neutrophil elastase while minimizing off-target activity.

SpA5 mutant protein triggers protective immune responses against Staphylococcus aureus infections by eliminating harmful antibody binding capacity.

Half-sandwich ruthenium complexes use glycopyranosyl azoles to overcome platinum resistance and reduce toxicity.

Formula I compounds modulate CFTR activity to improve chloride transport, addressing defective protein folding and trafficking.

Multi-strain phage cocktails target different bacterial receptors to prevent infection while preserving normal microbiota integrity.

Novel amino bisphenyl pentanoic acid derivatives inhibit neutral endopeptidase to block peptide degradation.

Selective adsorption of E-isomer onto active carbon removes impurities from aqueous cephem solutions, achieving Z-isomer purity above 99%.

2′-Chloro nucleoside analogs treat hepatitis C infections while reducing host toxicity and improving bioavailability.

Specific anti-Chi3L1 antibodies block inflammatory signaling pathways, resolving low therapeutic effectiveness in cancer and asthma treatments.

Pyrimidine compounds inhibit heat shock protein 90 to stabilize tau proteins and enhance amyloid-beta degradation.

Anti-Staphylococcus aureus antibody targets mutant protein SA1452, treating MRSA without cytotoxic side effects.

A polyethylene glycol and polyphenolic polymer blend adheres to diverse medical device substrates.

Formula I compounds inhibit USP7 enzyme activity, resolving insufficient efficacy and safety profiles of current small molecule inhibitors.

Tartaric acid coating on a bioadhesive textile layer prevents bacterial migration while maintaining skin tolerance above 80 percent.

Peptidoglycan inhibitor treatment converts Chlamydiaceae into non-infectious BL forms, resolving the contradiction between vaccine safety and immunogenicity.

Novel compounds inhibit cytochrome bc1 activity in Mycobacterium tuberculosis to disrupt bacterial energy production.

An anti-C3d antibody conjugate binds C3 protein fragments to form a detectable complex in biological fluids.

Formula Io 1 compounds inhibit 11β-HSD1 to reduce local cortisol regeneration, addressing inadequate treatment for obesity and metabolic syndrome.

Peptide-conjugated morpholino oligonucleotides with charged backbones bind bacterial RNA targets, bypassing antibiotic resistance mechanisms.

Compatible thickeners like PEG-150 stearate stabilize cationic compounds in alcohol sanitizers, preventing phase separation and skin dehydration.

Dibenzodiazepine compounds stimulate the STING pathway to induce antiviral and anti-tumor effects.

Combines daptomycin with protein synthesis inhibitors to prevent daptomycin non-susceptibility in MRSA strains.

Synthetic disaccharide hydrocarbons disperse pre-formed biofilms and inhibit adhesion, overcoming the low potency of natural rhamnolipids.

Novel pyrimidine-dione compound targets Mycobacterium tuberculosis with a unique mechanism of action.

Administering vaccines at three months gestation reduces cattle assembly frequency while ensuring robust neonatal diarrhea protection.

siRNA silences specific genes to lower intraocular pressure, addressing the trade-off between treatment duration and regimen complexity.

Macrocyclic compounds inhibit hepatitis C virus replication while reducing side effects and drug resistance.

Isolated polypeptides expressed under iron chelation bind antibodies to neutralize toxins and reduce colonization.

Liposomal saponin adjuvants enhance cross-protection against variant influenza strains while maintaining lower reactogenicity.

A brominated furanone derivative mimics bacterial signaling molecules to block communication pathways.

Lysosomotropic agents raise intracellular pH to revert dormant bacteria to a susceptible phenotype.

A colistin and fosfomycin association erodes biofilm matrices through membrane disruption and enzyme inhibition.

Triacetoxyborohydride enables rapid reductive amination of bacterial saccharides to carrier proteins.

Novel multi-functional peptides combine antibacterial activity with immune cell regulation through targeted receptor interaction.

Merges fosfomycin with enrofloxacin or pirlimycin to reduce bacterial populations and block clonal expansion of persisting variants.

A zinc-citrate ionic complex enhances metal ion bioavailability in oral care formulations.

Substituted quinoline compounds modulate the nuclear receptor RORγt to inhibit pathogenic Th17 cell activity.

A multivalent vaccine formulation combines five polypeptides to elicit dual immune responses against Staphylococcus aureus phenotypes.

Human monoclonal antibody mAb-B7 binds the EspB protein of the Type III secretion system.

Disubstituted pyridine derivatives inhibit CDK9 to treat cell proliferative and inflammatory diseases, overcoming limited specificity of prior art compounds.

Formula I compounds inhibit bacterial efflux pumps, lowering the minimum inhibitory concentration required to treat resistant strains.

Allosteric colicin forms ion channels in bacterial membranes to kill pathogens, bypassing biochemical resistance and reducing hypersensitivity reactions.

Cationic porphyrin derivatives selectively bind bacterial membranes to kill Gram-negative pathogens while reducing toxicity to mammalian host tissues.

A eutectic composition of geranic acid and choline dissolves essential oils in water.